Scintigraphic Assessment Following Klean-Prep® or Moviprep®

This study has been completed.
Sponsor:
Information provided by:
Norgine
ClinicalTrials.gov Identifier:
NCT00896246
First received: May 8, 2009
Last updated: May 11, 2009
Last verified: May 2009
  Purpose

This was a phase 1, open-label, randomized study, designed to assess the impact of Moviprep® or Klean-Prep® on gastrointestinal transit. It was performed in two parallel groups with Part A in two groups of four subjects preceding Part B, which was performed in two groups of 12 subjects. Subjects attended a pre-study medical within 28 days of dosing and a post-study medical 5-10 days after the final dose. Within both Part A and Part B, subjects were required to attend the clinical unit for 2 study periods. Part A consisted of a baseline period to determine individual reference times for gastrointestinal transit. Part B was the test period in which gastrointestinal transit following the administration of the test preparations was assessed.


Condition Intervention Phase
Gastric Emptying
Healthy
Drug: Klean-Prep®
Drug: Moviprep®
Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Pharmacokinetics/Dynamics Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Scintigraphic Assessment of Gastrointestinal Transit Following Administration of Klean-Prep® (4L) or Moviprep® (2L) to Healthy Volunteers.

Further study details as provided by Norgine:

Primary Outcome Measures:
  • To assess the impact of Moviprep® and Klean-Prep® on time of colonic transit of the contents of the colon in comparison to baseline [ Time Frame: 2-4 days ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • To assess the gastrointestinal transit of Moviprep® and Klean-Prep® in comparison to baseline [ Time Frame: 2-4 days ] [ Designated as safety issue: No ]
  • To determine gastric emptying of Moviprep® and Klean-Prep® [ Time Frame: 2-4 days ] [ Designated as safety issue: No ]
  • To collect information about stool weight, visual characteristics and distribution of the radiolabel [ Time Frame: 2-4 days ] [ Designated as safety issue: No ]

Enrollment: 32
Study Start Date: September 2006
Study Completion Date: November 2006
Primary Completion Date: October 2006 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Klean-Prep®
1 x gelatin capsule containing not more than 1 MBq 111In radiolabelled ion exchange resin plus Klean-Prep® (4 L) containing 99mTc-DTPA administered as a divided dose.
Drug: Klean-Prep®
Four litres of solution administered orally as a divided dose.
Experimental: Moviprep®
1 x gelatin capsule containing not more than 1 MBq 111In radiolabelled ion exchange resin plus Moviprep® (2 L) containing radiolabelled 99mTc-DTPA administered as a divided dose.
Drug: Moviprep®
Two litres of solution administered orally as a divided dose

  Eligibility

Ages Eligible for Study:   18 Years to 65 Years
Genders Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. Healthy males;
  2. Aged 18-65 years;
  3. Body Mass Index of 18-35 kg/m2;
  4. Must be willing and able to participate in the whole study and must provide written informed consent.

Exclusion Criteria:

  1. Participation in a clinical research study involving investigational drugs or dosage forms within the previous 3 months;
  2. Subjects who have previously been enrolled in this study;
  3. Subjects who have ever sought advice from or been referred to a GP or counsellor for abuse or misuse of alcohol, non medical drugs, medicinal drugs or other substance abuse e.g. solvents;
  4. Subjects who admit to any current or previous use of Class A drugs such as opiates, cocaine, ecstasy, LSD (d lysergic acid diethylamide) and intravenous amphetamines. Subjects who admit to occasional past use of cannabis will not be excluded as long as they have a negative drugs of abuse test and have abstained from cannabis use for at least 3 months;
  5. Positive drugs of abuse test result;
  6. Regular alcohol consumption > 21 units per week (1 Unit = ½ pint beer, a 25 mL shot of 40% spirit or a 125 mL glass of wine);
  7. Current smokers and those who have smoked within the last 12 months. A breath carbon monoxide reading of greater than 10 ppm at screening;
  8. Radiation exposure from clinical trials, including that from the present study and from diagnostic x rays but excluding background radiation, exceeding 5 mSv in the last twelve months or 10 mSv in the last five years. No occupationally exposed worker, as defined in the Ionising Radiation Regulations 1999, shall participate in the study;
  9. Clinically significant abnormal biochemistry, haematology or urinalysis as judged by the PMI;
  10. History of gastrointestinal surgery (with the exception of appendectomy unless it was performed within the previous 12 months);
  11. History of clinically significant cardiovascular, renal, hepatic, respiratory and particularly gastrointestinal disease, especially peptic ulceration, gastrointestinal bleeding, ulcerative colitis, Crohn's disease or Irritable Bowel Syndrome;
  12. Subjects with a hypersensitivity to any of the ingredients in either Moviprep® or Klean- Prep®;
  13. Diarrhoea or constipation in the 7 days before the predicted first study day. Diarrhoea will be defined as the passage of liquid faeces and/or a stool frequency of greater than three times per day. Constipation will be defined as a failure to open the bowels more frequently than every other day.
  14. Subjects will be excluded from the study if they are considered by the PMI to be at risk of transmitting, through blood or other body fluids, the agents responsible for AIDS (Acquired Immunodeficiency Syndrome), other sexually transmitted disease or hepatitis. This will be assessed by the use of a question which requires that a potential subject decides whether he fulfills any category included on a reference card. If the answer is 'yes', the subject is excluded from the study;
  15. Positive HBV, HCV or HIV results;
  16. Subjects receiving prohibited medication as described in Section 7.4. Subjects must not stop taking a prescribed medication for the purpose of entering the study;
  17. Subjects with a history of phenylketonuria or glucose-6-phosphate dehydrogenase deficiency;
  18. Failure to satisfy the PMI of fitness to participate for any other reason.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00896246

Locations
United Kingdom
Pharmaceutical Profiles Ltd
Nottingham, United Kingdom, NG11 6JS
Sponsors and Collaborators
Norgine
Investigators
Study Director: Hans-Jürgen Gruss, MD Norgine
Principal Investigator: Philip Evans, MB ChB MRCS Pharmaceutical Profiles Ltd
  More Information

No publications provided

Responsible Party: Dr Hans-Jürgen Gruss, Norgine Ltd
ClinicalTrials.gov Identifier: NCT00896246     History of Changes
Other Study ID Numbers: NRL994-01/2007 (GLO)
Study First Received: May 8, 2009
Last Updated: May 11, 2009
Health Authority: United Kingdom: Medicines and Healthcare Products Regulatory Agency

ClinicalTrials.gov processed this record on October 19, 2014